sacituzumab govitecan
gilead sciences
['bcsm', 'tropics-02', 'mbc']
tropics-02 presented by . sacituzumab-govitecan vs treatment of physician's choice in hr+/her2- mbc treated with prior endocrine therapy, cdk4/6i, and 2+ prior chemo. improved pfs. os not mature.
#asco22 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.